Domantis Limited

Cephalon Australia Pty. Ltd.

Benjamin P Woolven

Ian M Tomlinson

Steve Holmes

Jennifer A Lee

Gregory Paul Winter

Anthony Gerard Doyle

Philip Anthony Jennings

Armin Sepp

Rudolf M T De Wildt

Justian Craig Fox

Mary Frances Fitzgerald

Jennifer Luckett

Carolyn Enever

Amrik Basran

Neil D Brewis

Stanislas Blein

Ruud De Wildt

Kate Jones

Stanislas Charles Blein

Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.

Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue

The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.

Antagonists against TNFR1 and methods of use therefor

The present invention provides a recombinant domain antibody (dAb) which binds to human TNF&#x3b1;, the dAb comprising an immunoglobulin heavy or light chain variable domain comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Anti-inflammatory dAb

Agents that bind a target in pulmonary tissue for targeting respiratory diseases

The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-&#x3b1;, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

The present invention provides a domain antibody construct which binds to human TNF-&#x3b1;, with the construct comprising:

Domain antibody construct

Growing community of inventors

Cambridge, United Kingdom

Benjamin P Woolven